Trial Profile
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses (40 mg to 480 mg) of BI 201335 NA as Capsule(s) Administered to Healthy Male Subjects - a Randomised, Placebo-controlled (Within Dose Groups) and Double-blind Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 14 Jul 2014 New trial record